Longitudinal effects of ivacaftor and medicine possession ratio in people with the

Ivacaftor was the first therapy licensed to address the underlying defect in cystic fibrosis (CF). The improvements in lung function, nutritional status and pulmonary exacerbations in patients carrying aWe conducted a 5-year single-centre retrospective study of people with CF carrying the35 people were included. After commencing ivacaftor, FEVThe addition of ivacaftor provides acute benefits for people with the